Lucid Diagnostics (LUCD) Cash from Investing Activities (2021 - 2026)
Lucid Diagnostics (LUCD) posted Cash from Investing Activities of -$215000.0 for Q1 2026, down 321.57% on a QoQ basis from -$51000.0 in Q4 2025, and down 131.18% year-over-year from $689482.8 in Q1 2025.
Lucid Diagnostics (LUCD) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Lucid Diagnostics' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$215000.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 131.18% year-over-year to -$215000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319000.0 (up 54.56% YoY) and the FY2025 annual result came in at -$197000.0, up 69.5% from the prior year.
- Cash from Investing Activities was -$215000.0 for Q1 2026 at Lucid Diagnostics, down from -$51000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$14000.0 in Q3 2023 and bottomed at -$2.4 million in Q2 2022.
- A 5-year average of -$336687.5 and a median of -$120500.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 243500.0% — and 2023, when it jumped 99.38%.
- Lucid Diagnostics' Cash from Investing Activities stood at -$203000.0 in 2022, then increased by 13.79% to -$175000.0 in 2023, then tumbled by 48.0% to -$259000.0 in 2024, then surged by 80.31% to -$51000.0 in 2025, then plunged by 321.57% to -$215000.0 in 2026.
- Business Quant data shows LUCD's Cash from Investing Activities at -$215000.0 in Q1 2026, -$51000.0 in Q4 2025, and -$28000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.47 Bn | 176.17 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 129.01 Bn | 126.14 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.40 Bn | 44.73 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.46 Bn | 22.33 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Lucid Diagnostics | 129.97 Mn | 102.09 Mn | -325,000.00 | -215,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -215,000.00 |
| Mar 31, 2026 | -215,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Dec 31, 2025 | -51,000.00 |
| Sep 30, 2025 | -28,000.00 |
| Sep 30, 2025 | -28,000.00 |
| Jun 30, 2025 | -25,000.00 |
| Jun 30, 2025 | -25,000.00 |
| Mar 31, 2025 | -93,000.00 |
| Mar 31, 2025 | -93,000.00 |
| Dec 31, 2024 | -259,000.00 |
| Dec 31, 2024 | -259,000.00 |
| Sep 30, 2024 | -350,000.00 |
| Sep 30, 2024 | -350,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Mar 31, 2024 | -37,000.00 |
| Dec 31, 2023 | -175,000.00 |
| Dec 31, 2023 | -175,000.00 |
| Sep 30, 2023 | -14,000.00 |
| Sep 30, 2023 | -14,000.00 |